ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors

Cancer Letters

Volumn 328, Issue 1, 2013, Pages 144-151

  Huang, Cheng Po ^a   Tsai, Meng Feng ^b   Chang, Tzu Hua ^c   Tang, Wei Chien ^a   Chen, Su Yu ^a   Lai, Hsiao Hsuan ^a   Lin, Ting Yu ^a   Yang, James Chih Hsin ^a   Yang, Pan Chyr ^c   Shih, Jin Yuan ^c   Lin, Shwu Bin ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b DA YEH UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Aldehyde dehydrogenase 1A1; Cancer stem cell; Gefitinib resistance; Lung cancer; Tyrosine kinase inhibitor

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE 1A1; BMI1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ETOPOSIDE; FLUOROURACIL; GEFITINIB; KRUPPEL LIKE FACTOR 4; MESSENGER RNA; MYC PROTEIN; NESTIN; OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR NANOG; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SENSITIVITY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; HUMAN; HUMAN CELL; LUNG CANCER; MALE; MOUSE; NONHUMAN; PLEURA EFFUSION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASTIC STEM CELLS; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84868496506     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.08.021     Document Type: Article

References (47)

1. Molina J.R., Yang P., Cassivi S.D., Schild S.E., Adjei A.A. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin. Proc. 2008, 83:584-594.
2. Yang P. Epidemiology of lung cancer prognosis: quantity and quality of life. Methods Mol. Biol. 2009, 471:469-486.
3. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., Haber D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 2004, 350:2129-2139.
4. Paez J.G., Jänne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., Meyerson M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004, 304:1497-1500.
5. Herbst R.S., Fukuoka M., Baselga J. Gefitinib-a novel targeted approach to treating cancer. Nat. Rev. Cancer 2004, 4:956-965.
6. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the egfr kinase domain. PLoS Med. 2005, 2:e73.
7. Engelman J.A., Zejnullahu K., Mitsudomi T., Song Y., Hyland C., Park J.O., Lindeman N., Gale C.M., Zhao X., Christensen J., Kosaka T., Holmes A.J., Rogers A.M., Cappuzzo F., Mok T., Lee C., Johnson B.E., Cantley L.C., Janne P.A. Met amplification leads to gefitinib resistance in lung cancer by activating erbb3 signaling. Science 2007, 316:1039-1043.
8. Tan B.T., Park C.Y., Ailles L.E., Weissman I.L. The cancer stem cell hypothesis: a work in progress. Lab. Invest. 2006, 86:1203-1207.
9. Zhou B.B., Zhang H., Damelin M., Geles K.G., Grindley J.C., Dirks P.B. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat. Rev. Drug Discov. 2009, 8:806-823.
10. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
11. O'Brien C.A., Pollett A., Gallinger S., Dick J.E. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
12. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
13. Ginestier C., Hur M.H., Charafe-Jauffret E., Monville F., Dutcher J., Brown M., Jacquemier J., Viens P., Kleer C.G., Liu S., Schott A., Hayes D., Birnbaum D., Wicha M.S., Dontu G. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
14. Su Y., Qiu Q., Zhang, Jiang Z., Leng Q., Liu Z., Stass S.A., Jiang F. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol. Biomarkers Prev. 2010, 19:327-337.
15. Clay M.R., Tabor M., Owen J.H., Carey T.E., Bradford C.R., Wolf G.T., Wicha M.S., Prince M.E. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010, 32:1195-1201.
16. Jiang F., Qiu Q., Khanna A., Todd N.W., Deepak J., Xing L., Wang H., Liu Z., Su Y., Stass S.A., Katz R.L. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol. Cancer Res. 2009, 7:330-338.
17. X. Li, L. Wan, J. Geng, C.L. Wu, X. Bai, Aldehyde Dehydrogenase 1A1 possesses stem-like properties and predicts lung cancer patient outcome. J. Thorac. Oncol., 2012, May 21 (Epub ahead of print).
18. Chang T.H., Tsai M.F., Su K.Y., Wu S.G., Huang C.P., Yu S.L., Yu Y.L., Lan C.C., Yang C.H., Lin S.B., Wu C.P., Shih J.Y., Yang P.C. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor. Am. J. Respir. Crit. Care Med. 2011, 183:1071-1079.
19. Shih J.Y., Tsai M.F., Chang T.H., Chang Y.L., Yuan A., Yu C.J., Lin S.B., Liou G.Y., Lee M.L., Chen J.J., Hong T.M., Yang S.C., Su J.L., Lee Y.C., Yang P.C. Transcription repressor slug promotes carcinoma invasion and predicts outcome of patients with lung adenocarcinoma. Clin. Cancer Res. 2005, 11:8070-8078.
20. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., Hatooka S., Shinoda M., Takahashi T., Tatabe Y. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 2005, 23:2513-2520.
21. Wu S.G., Chang Y.L., Hsu Y.C., Wu J.Y., Yang C.H., Yu C.J., Tsai M.F., Shih J.Y., Yang P.C. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. Oncologist 2008, 13:1276-1284.
22. Conway T.F., Sabel M.S., Sugano M., Frelinger J.G., Egilmez N.K., Chen F., Bankert R.B. Growth of human tumor xenografts in SCID mice quantified using an immunoassay for tumor marker protein in serum. J. Immunol. Methods 2000, 233:57-65.
23. Basak S.K., Veena M.S., Oh S., Huang G., Srivatsan E., Huang M., Sharma S., Batra R.K. The malignant pleural effusion as a model to investigate intratumoral heterogeneity in lung cancer. PLoS One 2009, 4:e5884.
24. Yamasaki F., Johansen M.J., Zhang D., Krishnamurthy S., Felix E., Bartholomeusz C., Aguilar R.J., Kurisu K., Mills G.B., Hortobagyi G.N., Ueno N.T. Acquired resistance to erlotinib in A-431 epidermoid cancer cells requires down-regulation of MMAC1/PTEN and up-regulation of phosphorylated Akt. Cancer Res. 2007, 67:5779-5788.
25. Bianco R., Shin I., Ritter C.A., Yakes F.M., Basso A., Rosen N., Tsurutani J., Dennis P.A., Mills G.B., Arteaga C.L. Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 2003, 22:2812-2822.
26. Engelman J.A., Jänne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., Cantley L.C. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. USA 2005, 102:3788-3793.
27. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27:5497-5510.
28. Martelli A.M., Evangelisti C., Chiarini F., Grimaldi C., McCubrey J.A. The emerging role of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cell biology. Cancers 2010, 2:1576-1596.
29. Frederick B.A., Helfrich B.A., Coldren C.D., Zheng D., Chan D., Bunn P.A., Raben D. Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma. Mol Cancer Ther. 2007, 6:1683-1691.
30. Thomson S., Buck E., Petti F., Griffin G., Brown E., Ramnarine N., Iwata K.K., Gibson N., Haley J.D. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res. 2005, 65:9455-9462.
31. Yauch R.L., Januario T., Eberhard D.A., Cavet G., Zhu W., Fu L., Pham T.Q., Soriano R., Stinson J., Seshagiri S., Modrusan Z., Lin C.Y., O'Neill V., Amler L.C. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005, 11:8686-8698.
32. Singh A., Settleman J. EMT, cancer stem cells and drug resistance. an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
33. Graham S.M., Jørgensen H.G., Allan E., Pearson C., Alcorn M.J., Richmond L., Holyoake T.L. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002, 99:319-325.
34. Jørgensen H.G., Allan E.K., Jordanides N.E., Mountford J.C., Holyoake T.L. Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 2007, 109:4016-4019.
35. Konig H., Copland M., Chu S., Jove R., Holyoake T.L., Bhatia R. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells. Cancer Res. 2008, 68:9624-9633.
36. Frank N.Y., Schatton T., Frank M.H. The therapeutic promise of the cancer stem cell concept. J. Clin. Invest. 2010, 120:41-50.
37. Wang J., Wakeman T.P., Lathia J.D., Hjelmeland A.B., Wang X.F., White R.R., Rich J.N., Sullenger B.A. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28:17-28.
38. Leung E.L., Fiscus R.R., Tung J.W., Tin V.P., Cheng L.C., Sihoe A.D., Fink L.M., Ma Y., Wong M.P. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties. PLoS One 2010, 5:e14062.
39. Sung J.M., Cho H.J., Yi H., Lee C.H., Kim H.S., Kim D.K., Abd El-Aty A.M., Kim J.S., Landowski C.P., Hediger M.A., Shin H.C. Characterization of a stem cell population in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 2008, 371:163-167.
40. Sullivan J.P., Spinola M., Dodge M., Raso M.G., Behrens C., Gao B., Schuster K., Shao C., Larsen J.E., Sullivan L.A., Honorio S., Xie Y., Scaglioni P.P., DiMaio J.M., Gazdar A.F., Shay J.W., Wistuba I.I., Minna J.D. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res. 2010, 70:9937-9948.
41. Borovski T., De Sousa F., Melo E., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Res. 2011, 71:634-639.
42. Perona R., López-Ayllón B.D., de Castro Carpeño J., Belda-Iniesta C. A role for cancer stem cells in drug resistance and metastasis in non-small-cell lung cancer. Clin. Transl. Oncol. 2011, 13:289-293.
43. Sheehan J.P., Shaffrey M.E., Gupta B., Larner J., Rich J.N., Park D.M. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol. 2010, 6:1591-1601.
44. Kuo M.T. Roles of multidrug resistance genes in breast cancer chemoresistance. Adv. Exp. Med. Biol. 2007, 608:23-30.
45. Takara K., Sakaeda T., Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. Curr. Pharm. Des. 2006, 12:273-286.
46. Ozvegy-Laczka C., Hegedus T., Várady G., Ujhelly O., Schuetz J.D., Váradi A., Kéri G., Orfi L., Német K., Sarkadi B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. Mol. Pharmacol. 2004, 65:1485-1495.
47. Chen Y.J., Huang W.C., Wei Y.L., Hsu S.C., Yuan P., Lin H.Y., Wistuba I.I., Lee J.J., Yen C.J., Su W.C., Chang K.Y., Chang W.C., Chou T.C., Chou C.K., Tsai C.H., Hung M.C. Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells. PLoS One 2011, 6:e21428.